ABSTRACT
INTRODUCTION
First-line treatment using folinic acid, fluorouracil, and oxaliplatin (FOLFOX) or folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) combined with target therapy prolongs the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) patients compared with dual chemotherapy, particularly when administered www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 37), pp: 62339-62348 Bevacizumab: 5 mg/kg, Q2W. FOLFOXIRI: irinotecan 165 mg/m² intravenous infusion for 60 min, followed by an 85 mg/m² intravenous infusion of oxaliplatin given concurrently with leucovorin at a dose of 200 mg/m² for 120 min, followed by a 3200 mg/m² continuous infusion of fluorouracil for 48 h.
Meta-Analysis

FOLFIRI+bevacizumab.
Bevacizumab: 5 mg/kg, Q2W. FOLFIRI: irinotecan 180 mg/m 2 intravenous infusion for 60 min followed by a 200 mg/m² intra venous infusion of leucovorin for 120 min, a 400 mg/m² intravenous bolus of fluorouracil, and a 2400 mg/ m² continuous infusion of fluorouracil for 46h. [1] [2] [3] [4] [5] [6] [7] . A study that used a regression model to analyze the correlation between the percentages of patients treated with triplet chemotherapy and the outcomes, found that OS is prolonged [8] . However, this model was derived using the data of a single arm of a study of patients with mCRC who were administered chemotherapy as first-line treatment. Moreover, the dose intensities of chemotherapy and targeted therapy were not considered.
Randomized controlled trials (RCTs) compared the efficacy and toxicities of triple chemotherapy (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan [FOLFOXIRI] ) plus target therapy with those of triple or double chemotherapy (FOLFOX or FOLFIRI) plus target therapy [9] [10] [11] . The efficacies and toxicities of triple and double chemotherapy were compared as well. However, whether dose intensity is the most important prognostic factor is controversial. We asked therefore whether FOLFOXIRI plus target therapy administered as first-line treatment improves the prognosis of patients with mCRC and if there is a significant difference in efficacy between FOLFOXIRI and double chemotherapy plus target therapy?
RESULTS
The titles and abstracts of 248 studies were reviewed. After the initial screen, we performed a detailed assessment of potentially eligible papers and selected 11 papers and 2 abstracts of 10 randomized controlled trials (RCT) [1] [2] [3] [4] [5] [6] [7] [9] [10] [11] [12] [13] [14] (Figure 1 ). FIRE3 study [15] , PEAK study [16] and CALGB 80405 study [17] were not included because the regimens both in the experimental groups and the control groups were recognized as FOLFOX or FOLFIRI plus target therapy in our network meta-analysis. And the survival of these three studies were consistent with the studies included.
Study
Study design Treatment schedule followed by an 85 mg/m² intravenous infusion of oxaliplatin given concurrently with leucovorin at a dose of 200 mg/m² for 120 min, followed by a 3200 mg/m² continuous infusion of fluorouracil for 48 h.
FOLFOX + bevacizumab
Bevacizumab: 5 mg/kg Q2W. FOLFOX Q3W in a 4-6 month induction phase, followed by bevacizumab-containing maintenance treatment Abbreviations: Q2W, every 2 weeks; IV, intravenous. Table 1 shows the characteristics of these 10 RCTs. The patients with mCRC (n = 2,506) were randomized into treatment vs control groups (Table 1 ). Methodological quality assessment was performed according to the latest guidelines in the Cochrane Handbook for Systematic Reviews of Interventions. The quality of each included study was high ( Table 2 ). The network of the comparisons is shown in Figure  2 . Four regimens from 10 trails were included in the network. Four studies compared double chemotherapy plus target therapy with double chemotherapy. Four studies compared double chemotherapy plus target therapy with triple chemotherapy plus target therapy. Two studies compared triple chemotherapy with double chemotherapy.
The pooled HRs of PFS of patients administered an individual regimen compared with FOLFOX or FOLFIRI plus target therapy in the network meta-analysis shows that the PFS of patients administered FOLFOXIRI plus target therapy was longer compared with that of FOLFOX or FOLFIRI plus target therapy (HR 0.71, 95% CI 0.59-0.86) ( Figure 3A ). There was no difference between FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy (HR 1.23, 95% CI 0.87-1.72) ( Figure 3A) . Pooled HRs of OS of patients administered individual regimens compared with FOLFOX or FOLFIRI plus target therapy in the network meta-analysis shows that the OS of patients for FOLFOXIRI plus target therapy was longer compared with that of FOLFOX or FOLFIRI plus target therapy (HR 0.81, 95% CI 0.69-0.94) ( Figure 3B ). There was no difference between FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy (HR 0.94, 95% CI 0.66-1.35) ( Figure 3B) .
The pooled RRs of ORR of patients administered individual regimens compared with FOLFOX or FOLFIRI Figure 3C ). There was no difference between FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy (RR 0.89, 95% CI 0.37-2.15) ( Figure  3C ). The pooled RRs of the R0 resection rate of patients administered individual regimens compared with FOLFOX or FOLFIRI plus target therapy in the network meta-analysis shows that the R0 resection rate of patients administered FOLFOXIRI plus target therapy was higher compared with that of FOLFOX or FOLFIRI plus target therapy (RR 2.66, 95% CI 1.86-3.82) ( Figure 3D ). There was no significant difference between FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy (RR 1.87, 95% CI 0.77-4.50) ( Figure 3D ). The pooled RRs of toxicities of patients administered individual regimens compared with double chemotherapy plus targeted therapy in the network meta-analysis shows no increase in toxicities between FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy (Figure 4) . Further, FOLFOXIRI plus target therapy did not increase toxicities compared with FOLFOX or FOLFIRI plus target therapy ( Figure 4B) .
We also performed the subgroup analysis for the patients with RAS/BRAF mutations and the patients without RAS mutations. For the patients with RAS mutations (n = 454), FOLFOXIRI plus Bevacizumab (Bev) significantly prolonged the PFS compared with FOLFOX or FOLFIRI plus Bev (HR 0.75, 95% CI 0.62-0.92). For the patients with BRAF mutations (n = 54), FOLFOXIRI plus Bev prolonged the PFS compared with FOLFOX or FOLFIRI plus Bev, but the difference was not significant (HR 0.64, 95% CI 0.36-1.15). For the patients without RAS mutations (n = 292), FOLFOXIRI plus Bev significantly prolonged the PFS compared with FOLFOX or FOLFIRI plus Bev (HR 0.73, 95% CI 0.57-0.94) (Supplementary Figure 1) .
DISCUSSION
The results of this network meta-analysis show that first-line treatment using FOLFOXIRI plus target therapy prolonged PFS and OS and improved the ORR and R0 resection rate of patients with mCRC without a This study is the first to our knowledge to conduct a network meta-analysis that ranks the efficacy and toxicities of intensive therapy strategies. NCCN 2017 version 2 guidelines recommend a choice of FOLFOX, FOLFIRI, CapeOx, infusion 5-FU/LV or capecitabine, or FOLFOXIRI, with or without targeted agents as initial therapy for mCRC patients appropriate for intensive therapy. But which one is the best choice was still controversial. The 2016 ESMO guidelines recommend that the goal for treating patients with potentially resectable or nonresectable mCRC who have the ability to withstand intensive therapy should achieve shrinkage of clinically relevant tumors to the maximum extent possible [18] . Further, the 2016 ESMO guidelines state that for patients who are candidates for therapies that maximize tumor shrinkage or for those with BRAF mutations, the cytotoxic triplet FOLFOXIRI plus Bev is an option. But the grade of this evidence was IIB [18] .
Considering the absence of sufficient evidence, the application of intensive therapeutic strategies for treating patients with mCRC is limited. The results of our network meta-analysis suggest that patients with mCRC may benefit from FOLFOXIRI plus target therapy as first-line treatment. Therefore, FOLFOXIRI or FOLFOXIRI plus Bev may be a more suitable option for patients able to withstand intensive treatment. Moreover, the analysis of toxicities presented here show that FOLFOXIRI did not significantly increase toxicities compared with those associated with FOLFOX or FOLFIRI plus target therapy. And FOLFOXIRI plus target therapy also did not increase toxicities compared with those associated with FOLFOX or FOLFIRI plus target therapy, except for neutropenia.
The number of patients with mCRC who can afford target treatment is limited, and the efficacies and toxicities of triple chemotherapy and double chemotherapy plus target chemotherapy were not determined by RCTs. The results of our indirect comparison using network metaanalysis suggest that patients treated with FOLFOXIRI achieved similar PFS, OS, ORR, and R0 resection rates compared with patients treated with double chemotherapy This study did not analyze patients' ages or their performance status because only some certain criteria for the patients administered FOLFOXIRI with or without target therapy were referred in the included studies but not consistent. For example, in the STEAM study [11] , patients aged 18-75 years were required to meet Eastern Cooperative Oncology Group (ECOG) performance status ≤1. The inclusion criteria of the OLIVIA [10] , TRIBE [9] , and GONO [12] studies were age ≥18 years and ECOG performance status ≤1; age 18-70 years, ECOG performance status ≤2; and age 71-75-years, ECOG performance status = 0; respectively. In the HORG study [13] , which did not impose an age limit, 56% of patients treated with FOLFOXIRI were aged ≥65 years.
Our network meta-analysis has certain limitations. First, target therapy has been used as first-line treatment for mCRC since 2004. Thus, target therapy was not administered to study and control groups in the GONO study [12] , which may have biased the present data. Second, testing for RAS and BRAF mutations is not currently required for treatment using Bev, and the HRs of all patients without data for RAS mutational status included in the studies were administered bevacizumab but not an anti-EGFR antibody. Third, the number of eligible studies was small. Therefore, future RCTs must include larger numbers of subjects.
We conclude that FOLFOXIRI plus target therapy administered as first-line treatment is the best choice for patients with mCRC, because it is not significantly associated with increased toxicities. The patients with RAS/BRAF mutations could benefit from FOLFOXIRI plus Bev. Further, FOLFOXIRI is as effective as double chemotherapy plus target therapy.
MATERIALS AND METHODS
Search strategy
This network meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19] . We searched the abstracts of RCTs to evaluate the efficacies and toxicities of intensive therapies administered as first-line treatment of patients with mCRC. The resources searched included PubMed, the Cochrane Collaboration Central Register of Controlled Clinical Trials, Cochrane Systematic Reviews, ClinicalTrials.gov, and the databases of the European Society for Medical Oncology and American Society of Clinical. The search included articles dated from the inception of these resources until March 31, 2017 (the list of search terms is included in the Supplementary Data). We reviewed the bibliographies of these reports as well as related reviews to identify articles. These papers were subjected to manual searches. Our network meta-analysis included studies that compared different intensive therapies.
Quality assessment and data extraction
Two investigators (Z-MY, Y-P) independently reviewed the entire text of eligible studies. Information was extracted and inserted into an electronic database that included patient characteristics, inclusion and exclusion criteria, treatment protocols, and outcomes. Any disagreement between reviewers was discussed with the other coauthors until a consensus was reached.
Data synthesis and analysis
Outcomes of this study included progression-free survival (PFS), OS, ORR, and the R0 resection rate. Random-effects models were used to account for the heterogeneity among studies. Standard meta-analysis was performed using Stata 12.1 (StataCorp, College Station, TX, USA). Network meta-analysis was performed using a netmeta package developed according to the theories of a classical frequentist setting included in the R language framework.
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